Premium
Diffuse (anergic) cutaneous leishmaniasis responding to amphotericin B
Author(s) -
Morrison B.,
Mendoza I.,
Delgado D.,
Reyes Jaimes O.,
Aranzazu N.,
Paniz Mondolfi A. E.
Publication year - 2010
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.2009.03737.x
Subject(s) - medicine , cutaneous leishmaniasis , leishmaniasis , amphotericin b , leprosy , disease , dermatology , leishmania , immunology , miltefosine , pathology , visceral leishmaniasis , antifungal , parasite hosting , world wide web , computer science
Summary American cutaneous leishmaniasis is an important endemic zoonotic disease in the New World that comprises a spectrum of clinical manifestations. Diffuse cutaneous leishmaniasis (DCL) is a rare form of the disease characterized by antigen‐specific immunodeficiency that often presents with multiple disfiguring non‐ulcerated confluent nodules or plaques that involve large areas of the skin, resembling lepromatous leprosy. Relapse is invariable in advanced stages, despite aggressive chemotherapy, and a plethora of drugs has been tested with unchanging results. We report on a severe an exceptional case that resolved after treatment with amphotericin B, a drug considered only mildly effective, and discuss the therapeutic approach to this disease.